Radium Dichloride

CHEMBL2111187 Phase 4 Disetujui Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

Radium dichloride (radium-223 dichloride, Xofigo) is a targeted alpha-emitting radiopharmaceutical that, as a calcium mimetic, selectively incorporates into areas of increased bone turnover (osteoblastic metastases), delivering high-linear-energy-transfer alpha radiation to metastatic foci while minimizing systemic exposure. It is approved for the treatment of castration-resistant prostate cancer with symptomatic bone metastases and no known visceral metastatic disease.

Area Terapeutik

Mekanisme Kerja

Contains a radioactive isotope that accumulates in specific tissues or organs, enabling detection and imaging of physiological processes or pathological conditions using nuclear medicine techniques.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanisme

Contains a radioactive isotope that accumulates in specific tissues or organs, enabling detection and imaging of physiological processes or pathological conditions using nuclear medicine techniques.

Struktur 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Cl[Ra]Cl

InChI

InChI=1S/2ClH.Ra/h2*1H;/q;;+2/p-2

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

Radium dichloride (radium-223 dichloride, Xofigo) is a targeted alpha-emitting radiopharmaceutical that, as a calcium mimetic, selectively incorporates into areas of increased bone turnover (osteoblastic metastases), delivering high-linear-energy-transfer alpha radiation to metastatic foci while minimizing systemic exposure. It is approved for the treatment of castration-resistant prostate cancer with symptomatic bone metastases and no known visceral metastatic disease.

Contains a radioactive isotope that accumulates in specific tissues or organs, enabling detection and imaging of physiological processes or pathological conditions using nuclear medicine techniques.

Yes, Radium Dichloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2111187. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.